Non-convulsive seizure related to Cremophor EL™-free,polymeric micelle formulation of paclitaxel: A case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Y.S. | - |
dc.contributor.author | Min, K.J. | - |
dc.contributor.author | Choi, S.Y. | - |
dc.contributor.author | Lee, N.W. | - |
dc.date.accessioned | 2021-09-02T20:17:33Z | - |
dc.date.available | 2021-09-02T20:17:33Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 2287-8572 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/80396 | - |
dc.description.abstract | Paclitaxel is a chemotherapeutic agent that is effective against ovarian, breast, lung, and other cancers. Although peripheral neurotoxicity is among the most common side effects of paclitaxel treatment, central neurotoxicity is rarely reported. When centrally mediated side effects are observed, they are attributed to Cremophor EL™ (CrEL), a surfactant-containing vehicle used for paclitaxel administration. In the present report, we discuss the case of a 72-yearold woman with ovarian carcinoma who experienced a non-convulsive seizure following administration of a CrELfree, polymeric micelle formulation of paclitaxel. One week after her fourth round of chemotherapy, she experienced a transient episode of aphasia for 45 minutes. Electroencephalography demonstrated epileptiform discharges. To our knowledge, this is the first reported case of seizure associated with a CrEL-free formulation of paclitaxel. Although rare, patients and clinicians should remain aware of the risk of non-convulsive seizure following infusion of this paclitaxel formulation. ©2018 Korean Society of Obstetrics and Gynecology. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Obstetrics and Gynecology | - |
dc.title | Non-convulsive seizure related to Cremophor EL™-free,polymeric micelle formulation of paclitaxel: A case report | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Min, K.J. | - |
dc.identifier.doi | 10.5468/ogs.2018.61.3.421 | - |
dc.identifier.scopusid | 2-s2.0-85047081861 | - |
dc.identifier.bibliographicCitation | Obstetrics and Gynecology Science, v.61, no.3, pp.421 - 424 | - |
dc.relation.isPartOf | Obstetrics and Gynecology Science | - |
dc.citation.title | Obstetrics and Gynecology Science | - |
dc.citation.volume | 61 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 421 | - |
dc.citation.endPage | 424 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002346814 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Cremophor | - |
dc.subject.keywordAuthor | Neurotoxicity | - |
dc.subject.keywordAuthor | Paclitaxel | - |
dc.subject.keywordAuthor | Seizures | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.